Avanos Medical (AVNS)
(Delayed Data from NYSE)
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.80 USD
+0.15 (0.66%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $22.81 +0.01 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
B Value D Growth C Momentum C VGM
Zacks News
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Neogen (NEOG) Receives New Label Claims for Viroxide Super
by Zacks Equity Research
Neogen's (NEOG) Viroxide Super active constituents are potassium peroxymonosulfate and sodium chloride, which have been verified effective against multiple industry-relevant bacteria and viruses.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions
by Zacks Equity Research
Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.
Henry Schein (HSIC) Bolsters Dental Practices With AI Tools
by Zacks Equity Research
Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.
The Joint (JYNT) to Enter Puerto Rico With New Franchise Deal
by Zacks Equity Research
The Puerto Rico deal with the Comerfords marks The Joint's (JYNT) first franchise deal outside the continental United States.
Is Avanos Medical (AVNS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage
by Zacks Equity Research
With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.
Merit Medical's (MMSI) New Launch to Boost its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly enhance patient outcomes.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
BD's (BDX) New FDA Approval to Improve Vaginitis Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.
Humana (HUM) Rises 9.7% in a Year: More Room for Growth?
by Zacks Equity Research
Humana's (HUM) individual Medicare Advantage membership growth is likely to boost premium income.
Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.
Shockwave Medical (SWAV) Launches New IVL Catheter in U.S.
by Zacks Equity Research
Shockwave Medical's (SWAV) latest U.S. launch is expected to serve a wider patient pool.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up
by Zacks Equity Research
OPKO Health's (OPK) entry into a worldwide license and collaboration agreement with Merck is expected to aid in developing a vaccine against EBV.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.
Encompass Health's (EHC) 155th Hospital Opens in Wisconsin
by Zacks Equity Research
The Rehabilitation Hospital of Western Wisconsin is Encompass Health's (EHC) first location in the state.
UnitedHealth (UNH) Plan in Indiana to Offer Pathways Program
by Zacks Equity Research
UnitedHealth (UNH) expects the new Pathways for Aging program to serve around 100,000 people.
Brookdale Senior (BKD) February Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 16 straight months of year-over-year increases in weighted average occupancy level.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips
by Zacks Equity Research
Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.